<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10487619</article-id><article-id pub-id-type="pmc">2374352</article-id><article-id pub-id-type="pii">6690657</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690657</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thomson</surname><given-names>A H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vasey</surname><given-names>P A</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>L S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fraier</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frigerio</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Twelves</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine &#x00026; Therapeutics, University of Glasgow, <label>2</label>CRC Department of Medical Oncology Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT, UK</aff><aff id="aff3"><label>3</label>Bioanalytical Laboratory Pharmacokinetics and Metabolism Department, Pharmacia &#x00026; Upjohn, Nerviano, Italy</aff><aff id="aff4"><label>4</label>Department of Medicine &#x00026; Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK</aff><pub-date pub-type="ppub"><month>09</month><year>1999</year></pub-date><volume>81</volume><issue>1</issue><fpage>99</fpage><lpage>107</lpage><history><date date-type="received"><day>19</day><month>11</month><year>1998</year></date><date date-type="rev-recd"><day>25</day><month>03</month><year>1999</year></date><date date-type="accepted"><day>12</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20&#x02013;320 mg m<sup>&#x02212;2</sup> HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since assay constraints limited the data at lower doses, conventional analysis was not feasible and a &#x02018;population approach&#x02019; was used. Bound concentrations were best described by a biexponential model and further analyses revealed a small influence of dose or weight on V1 but no identifiable effects of age, body surface area, renal or hepatic function. The final model was: clearance (Q) 0.194 l h<sup>&#x02212;1</sup>; central compartment volume (V1) 4.48 &#x000d7; (1+0.00074 &#x000d7; dose (mg)) l; peripheral compartment volume (V2) 7.94 l; intercompartmental clearance 0.685 l h<sup>&#x02212;1</sup>. Distribution and elimination half-lives had median estimates of 2.7 h and 49 h respectively. Free doxorubicin was present at most sampling times with concentrations around 1000 times lower than bound doxorubicin values. Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 l h<sup>&#x02212;1</sup>; apparent V1 (l) 1450 &#x000d7; (1+0.0013 &#x000d7; dose (mg)), apparent V2 (l) 21 300 &#x000d7; (1&#x02013;0.0013 &#x000d7; dose (mg)) &#x000d7; (1+2.95 &#x000d7; height (m)) and apparent Q 6950 l h<sup>&#x02212;1</sup>. Distribution and elimination half-lives were 0.13 h and 85 h respectively. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>PK1-doxorubicin</kwd><kwd>solid tumours</kwd><kwd>population pharmacokinetics</kwd></kwd-group></article-meta></front></article>


